Thiamin Deficiency in Obese Thai Children

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02464865

Enrollment

124

Registered

2015-06-08

Start date

2015-08-31

Completion date

2018-08-31

Last updated

2018-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child, Obesity, Thiamine Deficiency

Keywords

thiamine deficiency, obese children, Thai

Brief summary

This study is aimed to assess the prevalence of thiamin deficiency in obese Thai children.

Detailed description

This study is a cross-sectional study. The objectives of the study are to determine the prevalence of thiamin deficiency in obese Thai children and to assess the associations of dietary factors and thiamin deficiency.

Interventions

DRUGThiamine 1

If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed. Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks

OTHERNon-thiamine

no symptoms and signs of thiamine deficiency

DRUGThiamine 2

If symptoms and signs of thiamine deficiency are present, thiamine is prescribed. If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

7 Years to 15 Years

Healthy volunteers

Yes

Inclusion criteria

* obese : weight for height \> median + 3 standard deviations * simple obesity

Exclusion criteria

* pathological obesity * chronic diseases e.g. cerebral palsy, metabolic disease, etc. * diseases of red blood cells * on medication e.g. steroid, multivitamins, thiamine-containing vitamins, diuretic drugs * hemodialysis or peritoneal dialysis * bariatric surgery

Design outcomes

Primary

Measure	Time frame	Description
abnormal thiamin pyrophosphate effect	7 days	Thiamin pyrophosphate effect will be measured by a blood test

Secondary

Measure	Time frame	Description
consumption of thiaminase-containing foods and thiamin antagonist-containing foods	7 days	Food diary and food frequency questionaire will be required to evaluate food consumption

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026